ATROPINE SULFATE solution/ drops

Atropine Sulfate by

Drug Labeling and Warnings

Atropine Sulfate by is a Prescription medication manufactured, distributed, or labeled by NorthStar RxLLC, Mankind Pharma Limited. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1 INDICATIONS AND USAGE

    Atropine Sulfate Ophthalmic Solution, 1% is indicated in adults and pediatric patients aged three (3) months and older for:

     

    1.1 Cycloplegia

    1.2 Mydriasis

    1.3 Penalization of the Healthy Eye in the Treatment of Amblyopia

  • 2 DOSAGE AND ADMINISTRATION

    • Apply 1 drop topically to the cul-de-sac of the conjunctiva, forty minutes prior to the intended maximal dilation time.
    • In adults and pediatric patients aged 3 years and older, doses may be repeated up to twice daily as needed.
  • 3 DOSAGE FORMS AND STRENGTHS

    Atropine Sulfate Ophthalmic Solution, USP 1%: each mL contains 10 mg of atropine sulfate equivalent to 8.3 mg of atropine

  • 4 CONTRAINDICATIONS

    4.1 Hypersensitivity

    Atropine Sulfate Ophthalmic Solution 1% is contraindicated in patients who have demonstrated a previous hypersensitivity or known allergic reaction to any ingredient of the formulation.

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Photophobia and Blurred Vision

    Photophobia and blurred vision due to pupil unresponsiveness and cycloplegia may last up to 2 weeks.

     

    5.2 Elevation of Blood Pressure

    Elevations in blood pressure from systemic absorption has been reported following conjunctival instillation of recommended doses of Atropine Sulfate Ophthalmic Solution, 1%.

    5.3 Risk of Contamination

    Do not touch the dropper tip to the eye, eyelids, or any other surface as this may contaminate the solution.

  • 6 ADVERSE REACTIONS

    The following serious adverse reactions are described below and elsewhere in the labeling:

    • Photophobia and Blurred Vision [See Warnings and Precautions (5.1)]
    • Elevation in Blood Pressure [See Warnings and Precautions (5.2)]

    The following adverse reactions were identified in clinical studies or postmarketing reports following use of atropine sulfate ophthalmic solution. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

    6.1 Ocular Adverse Reactions

    Eye pain and stinging occurs upon instillation. Other commonly occurring adverse reactions include, blurred vision, photophobia, superficial keratitis and decreased lacrimation. Allergic reactions such as papillary conjunctivitis, contact dermatitis, and lid edema may also occur less commonly.

    6.2 Systemic Adverse Reactions

    Systemic effects of atropine are related to its anti-muscarinic activity. Systemic adverse events reported include dryness of skin, mouth, and throat from decreased secretions from mucus membranes; restlessness, irritability or delirium from stimulation of the central nervous system; tachycardia; flushed skin of the face and neck.

  • 7 DRUG INTERACTIONS

    7.1 Monoamine Oxidase Inhibitors (MAOI)

    The use of atropine and monoamine oxidase inhibitors (MAOI) is generally not recommended because of the potential to precipitate hypertensive crisis.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    There are no adequate and well-controlled studies of atropine sulfate administration in pregnant women to inform a drug-associated risk. Adequate animal development and reproduction studies have not been conducted with atropine sulfate. In humans, 1% atropine sulfate is systemically bioavailable following topical ocular administration [see Clinical Pharmacology (12.3)].

    Atropine Sulfate Ophthalmic Solution 1% should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus.

    8.2 Lactation

    Risk Summary

    There is no information to inform risk regarding the presence of atropine in human milk following ocular administration of atropine sulfate to the mother. The effects on breastfed infants and the effects on milk production are also unknown. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for atropine sulfate and any potential adverse effects on the breastfed child from atropine sulfate.

    8.4 Pediatric Use

    The safety and effectiveness of Atropine Sulfate Ophthalmic Solution 1% have been established in pediatric patients aged 3 months and older. Use of Atropine Sulfate Ophthalmic Solution 1% is supported by evidence from adequate and well-controlled trials with additional safety data from published literature.

    Due to the potential for systemic absorption, the use of Atropine Sulfate Ophthalmic Solution 1% in pediatric patients aged 3 months to 3 years should be limited to no more than one drop per eye per day.

    Use in pediatric patients younger than 3 months of age is not recommended.

    8.5 Geriatric Use

    No overall differences in safety and effectiveness have been observed between elderly and younger adult patients.

  • 10 OVERDOSAGE

    In the event of accidental ingestion or toxic overdosage with atropine sulfate ophthalmic solution, supportive care may include a short acting barbiturate or diazepam as needed to control marked excitement and convulsions. Large doses for sedation should be avoided because central depressant action may coincide with the depression occurring late in atropine poisoning. Central stimulants are not recommended.

    Physostigmine, given by slow intravenous injection of 1 to 4 mg (0.5 to 1 mg in pediatric populations), rapidly abolishes delirium and coma caused by large doses of atropine. Since physostigmine is rapidly destroyed, the patient may again lapse into coma after one to two hours, and repeated doses may be required.

    Artificial respiration with oxygen may be necessary. Cooling measures may be needed to help to reduce fever, especially in pediatric populations.

    The fatal adult dose of atropine is not known. In pediatric patients, 10 mg or less may be fatal.

  • 11 DESCRIPTION

    Atropine Sulfate Ophthalmic Solution, USP 1% is a sterile topical anticholinergic for ophthalmic use. The active ingredient is represented by the chemical structure:

    structure

    Chemical Name: Benzeneacetic acid, α-(hydroxymethyl)-, 8-methyl-8-azabicyclo[3.2.1.]oct-3-yl ester, endo –(±)-, sulfate (2:1) (salt), monohydrate.

    Molecular Formula: (C17H23NO3)2   H2SO4  H2O

    Molecular Weight: 694.84 g/mol

    Atropine sulfate, USP appears as colorless, almost white to white solid. It is very soluble in water and glacial acetic acid, freely soluble in ethanol (96%) and practically insoluble in diethyl ether.

    Each mL of Atropine Sulfate Ophthalmic Solution USP, 1% contains: Active: atropine sulfate, USP 10 mg equivalent to 8.3 mg of atropine. Inactives: benzalkonium chloride 0.1 mg (0.01%), dibasic sodium phosphate anhydrous, edetate disodium dihydrate, hypromellose (2910), monobasic sodium phosphate monohydrate, hydrochloric acid and/or sodium hydroxide may be added to adjust pH (3.5 to 6.0), and water for injection USP.

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Atropine is a reversible antagonist of muscarine-like actions of acetyl-choline and is therefore classified as an antimuscarinic agent. Atropine is relatively selective for muscarinic receptors. Its potency at nicotinic receptors is much lower, and actions at non-muscarinic receptors are generally undetectable clinically. Atropine does not distinguish among the M1, M2, and M3 subgroups of muscarinic receptors.

    The pupillary constrictor muscle depends on muscarinic cholinoceptor activation. This activation is blocked by topical atropine resulting in unopposed sympathetic dilator activity and mydriasis. Atropine also weakens the contraction of the ciliary muscle, or cycloplegia. Cycloplegia results in loss of the ability to accommodate such that the eye cannot focus for near vision.

    12.2 Pharmacodynamics

    The onset of action after administration of atropine sulfate ophthalmic solution 1%, is usually within 40 minutes with maximal effect being reached in about 2 hours. The effect can last for up to 2 weeks in a normal eye.

    12.3 Pharmacokinetics

    The bioavailability of atropine sulfate ophthalmic solution 1% was assessed in six healthy subjects, 24 to 29 years of age. Subjects received either 0.3 mg atropine sulfate administered as bolus intravenous injection or 0.3 mg administered as 30 μL instilled unilaterally in the cul-de-sac of the eye. Plasma l-hyoscyamine concentrations were determined over selected intervals up to eight hours after dose administration.

    The mean bioavailability of topically applied atropine was 63.5 ± 29% (range 19 to 95%) with large inter-individual differences. Mean maximum observed plasma concentration for the ophthalmic solution was 288 ± 73 pg/mL. Maximum concentration was reached in 28 ± 27 min after administration. Terminal half-life of l-hyoscamine was not affected by route of administration and was calculated to be 3 ± 1.2 hours (intravenous) and 2.5 ± 0.8 hours (topical ophthalmic).

    In another placebo-controlled study, the systemic exposure to l-hyoscyamine, and the anti-cholinergic effects of atropine were investigated in eight ocular surgery patients 56 to 66 years of age, following single topical ocular 0.4 mg atropine dose (given as 40 microliters of atropine sulfate ophthalmic solution, 1%). The mean (± standard deviation (SD)) Cmax of l-hyoscyamine in these patients was 860 ± 402 pg/mL, achieved within 8 minutes of eyedrop instillation.

    Following intravenous administration, the mean (± SD) elimination half-life (t1/2) of atropine was reported to be longer in pediatric subjects under 2 years (6.9 ± 3.3 hours) and in geriatric patients 65 to 75 years (10.0 ± 7.3 hours), compared to in children over 2 years (2.5 ± 1.2 hours) and in adults 16 to 58 years (3.0 ± 0.9 hours). [see Use in Specific Populations (8.4)].

    Atropine is destroyed by enzymatic hydrolysis, particularly in the liver; from 13 to 50% is excreted unchanged in the urine. Traces are found in various secretions, including milk. The major metabolites of atropine are noratropine, atropin-n-oxide, tropine, and tropic acid. Atropine readily crosses the placental barrier and enters the fetal circulation, but is not found in amniotic fluid.

    Atropine binds poorly (about 44%) to plasma protein, mainly to alpha-1 acid glycoprotein; age has no effect on the serum protein binding of atropine. Atropine binding to α-1 acid glycoprotein was concentration dependent (2 to 20 mcg/mL) and nonlinear in vitro and in vivo. There is no gender effect on the pharmacokinetics of atropine administered by injection.

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    Carcinogenesis

    Long term studies in animals have not been performed to evaluate the carcinogenic potential of atropine sulfate.

    Mutagenesis

    Atropine sulfate was negative in the salmonella/microsome mutagenicity test.

    Impairment of Fertility

    Studies to evaluate impairment of fertility have not been conducted.

  • 14 CLINICAL STUDIES

    Topical administration of Atropine Sulfate Ophthalmic Solution 1% results in cycloplegia and mydriasis which has been demonstrated in several controlled clinical studies in adults and pediatric patients. Maximal mydriasis usually occurs in about 40 minutes and maximal cycloplegia is usually achieved in about 60 to 90 minutes after single administration. Full recovery usually occurs in approximately one week, but may last a couple of weeks.

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    Atropine Sulfate Ophthalmic Solution, USP 1% is supplied as clear, colorless solution in a three piece white bottle with a natural nozzle and red cap in the following sizes:

    NDC: 72603-264-01    2 mL fill in 5 mL bottle

    NDC: 72603-264-02    5 mL fill in 5 mL bottle

    Storage: Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Keep container tightly closed. After opening, Atropine Sulfate Ophthalmic Solution can be used until the expiration date on the bottle.

  • 17 PATIENT COUNSELING INFORMATION

    Risk of Contamination

    Advise patients to not touch the dropper tip to the eye, eyelids, or any other surface as this may contaminate the solution. Keep the bottle tightly closed.

    Instillation Site Pain 

    Advise patients that drops will sting upon instillation.

    Sensitivity to Light and Blurred Vision

    Advise patients that they will experience sensitivity to light and blurred vision which may last for a couple of weeks.

    Manufactured for:

    NorthstarRxLLC

    Memphis, TN 38141.

    Manufactured by:

    Mankind Pharma Limited

    Paonta Sahib, Sinnaur

    Himachal Pradesh 173025, India.

    Revised: September 2025, V-02

  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

    NDC: 72603-264-01

    Atropine Sulfate Ophthalmic Solution, USP

    1%

    2 mL

    Rx only

    Sterile

    2mlbottlelabel

    NDC: 72603-264-01

    Atropine Sulfate Ophthalmic Solution, USP

    1%

    2 mL

    Rx only

    Sterile

    2mlcartonlabel

    NDC: 72603-264-02

    Atropine Sulfate Ophthalmic Solution, USP

    1%

    5 mL

    Rx only

    Sterile

    5mlbottlelabel

    NDC: 72603-264-02

    Atropine Sulfate Ophthalmic Solution, USP

    1%

    5 mL

    Rx only

    Sterile

    5mlcartonlabel
  • INGREDIENTS AND APPEARANCE
    ATROPINE SULFATE 
    atropine sulfate solution/ drops
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 72603-264
    Route of AdministrationOPHTHALMIC
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    ATROPINE SULFATE (UNII: 03J5ZE7KA5) (ATROPINE - UNII:7C0697DR9I) ATROPINE SULFATE10 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    HYPROMELLOSE 2910 (4000 MPA.S) (UNII: RN3152OP35)  
    SODIUM PHOSPHATE, DIBASIC, ANHYDROUS (UNII: 22ADO53M6F)  
    SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE (UNII: 593YOG76RN)  
    EDETATE DISODIUM (UNII: 7FLD91C86K)  
    BENZALKONIUM CHLORIDE (UNII: F5UM2KM3W7)  
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    HYDROCHLORIC ACID (UNII: QTT17582CB)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 72603-264-011 in 1 CARTON09/01/2024
    12 mL in 1 BOTTLE; Type 9: Other Type of Part 3 Combination Product (e.g., Drug/Device/Biological Product)
    2NDC: 72603-264-021 in 1 CARTON09/01/2024
    25 mL in 1 BOTTLE; Type 9: Other Type of Part 3 Combination Product (e.g., Drug/Device/Biological Product)
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA21814809/01/2024
    Labeler - NorthStar RxLLC (830546433)
    Registrant - Mankind Pharma Limited (915834068)
    Establishment
    NameAddressID/FEIBusiness Operations
    Mankind Pharma Limited916512493MANUFACTURE(72603-264) , ANALYSIS(72603-264) , PACK(72603-264)
    • © 2025 FDA.report
    This site is not affiliated with or endorsed by the FDA.